GlassScriptPhysician profile
Barbara L Schwartz
NPI 1437101953
$9,331.78
in general payments reported to CMS, 2019-2025
51 companies · $842 in 2025
The $842 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,789 · 2020: $1,304 · 2021: $1,678 · 2022: $1,466 · 2023: $1,163 · 2024: $1,091 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,095.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,870.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,278.14 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $879.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $518.24 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.98 | 2019-2025 | Jardiance |
| Abbvie INC. | $427.30 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $424.24 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $352.10 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $249.64 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $226.56 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $207.01 | 2019-2025 | |
| Ibsa Pharma INC. | $197.22 | 2019-2023 | Tirosint, Licart |
| Merck Sharp & Dohme LLC | $185.79 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $179.07 | 2019-2024 | |
| Gilead Sciences, INC. | $144.59 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.